Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer

Anti-Cancer Drugs

Volumn 22, Issue 3, 2011, Pages 283-289

  Guerrero, Antonio ^a   Servitja, Sonia ^b   Rodríguez Lescure, Alvaro ^c   Calvo, Lourdes ^d   Del Barco, Sonia ^e   Quintanar, María Teresa ^c   Juárez, José Ignacio ^f   Gayo, Javier ^f   Llombart, Antonio ^a   Tusquets, Ignasi ^b  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f Centre d'Immunologie Pierre Fabre   (France)

Author keywords

anticancer drug combinations; biweekly drug administration schedule; cancer chemotherapy protocols; clinical trial; metastatic breast cancer; phase I; phase II

Indexed keywords

NAVELBINE; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST CANCER; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HUMAN; LEUKOPENIA; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SPAIN; VINBLASTINE;

EID: 79951679048     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3283425c55     Document Type: Article

References (29)

1. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742-1750. (Pubitemid 41437440)
2. Chia SK, Speers CH, D'Yachkova Y, Kang A, Malfair-Taylor S, Barnett J, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973-979. (Pubitemid 47312861)
3. National Cancer Institute (NCI). Surveillance Epidemiology and End Results (SEER) cancer statistics review 1999-2005. http://www.seer.cancer.gov/ csr/1975-2006/browse-csr.php?section = 4&page = sect-04-table.12. html#table3. [Accessed on 8 February 2010]
4. Insa A, Lluch A, Prosper F, Marugan I, Martinez-Agullo A, Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999; 56:67-78. (Pubitemid 29435816)
5. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist 2005; 10 (Suppl 3):20-29. (Pubitemid 43152727)
6. Gligorov J, Lotz JP. Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2008; 112 (Suppl 1):53-66.
7. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; 15:CD003372.
8. Dean-Colomb W, Esteva FJ. Emerging agents in the treatment of anthracycline-and taxane-refractory metastatic breast cancer. Semin Oncol 2008; 35 (2 Suppl 2):S31-S38. quiz S40. (Pubitemid 351503597)
9. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008; 34:378-390.
10. Moreno-Aspitia A, Perez EA. Anthracycline-and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009; 31:1619-1640.
11. Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27:1753-1760.
12. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, et al. Randomized phase III trial ofcapecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799. (Pubitemid 46224178)
13. Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 2008; 26:5544-5552.
14. Mart́in M, Ruíz A, Muñóz M, Balil A, García-Mata J, Calvo L, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8:219-225. (Pubitemid 46291704)
15. Vinorelbine (Navelbine) http://www.accessdata.fda.gov/drugsatfda-docs/ label/2002/20388S014lbl.pdf. [Accessed February 2010]
16. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-1252. (Pubitemid 23199126)
17. Garcia-Conde J, Lluch A, Martin M, Casado A, Gervasio H, De Oliveira C, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5:854-857. (Pubitemid 24341882)
18. Oxaliplatin http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 021492s011,021759s009lbl.pdf. [Accessed February 2010]
19. Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (2 Suppl 5):4-12. (Pubitemid 28248696)
20. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52:1855-1865. (Pubitemid 26419675)
21. Raymond E, Chaney SG, Taamma A, Cvitkovic E. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998; 9:1053-1071. (Pubitemid 28518143)
22. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappala AR, et al. Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001; 12:179-182. (Pubitemid 32223864)
23. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, et al. Phase II study of oxaliplatin and fluorouracil in taxane-and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20:2551-2558. (Pubitemid 34525743)
24. Delozier T, Guastalla JP, Yovine A, Levy C, Chollet P, Mousseau M, et al. A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anticancer Drugs 2006; 17:1067-1073. (Pubitemid 44454784)
25. Kakolyris S, Kouroussis C, Koukourakis M, Mavroudis D, Malas K, Vardakis N, et al. A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors. Oncology 2002; 63:213-218. (Pubitemid 36151314)
26. Caussanel JP, Lévi F, Brienza S, Misset JL, Itzhaki M, Adam R, et al. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82:1046-1050. (Pubitemid 20204976)
27. Petit T, Benider A, Yovine A, Bougnoux P, Spaeth D, Maindrault-Goebel F, et al. Phase II study of an oxaliplatin/vinorelbine combination in patients with anthracycline-and taxane-pre-treated metastatic breast cancer. Anticancer Drugs 2006; 17:337-343.
28. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53:615-627. (Pubitemid 34177898)
29. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-931. (Pubitemid 27282064)